WE CLAIM:

1. A compound of formula (I)



(I)

wherein

Cy is a non-aromatic carbocycle or heterocycle optionally substituted with hydroxyl, mercapto, thioalkyl, halogen, oxo, thio, amino, aminoalkyl, amidine, guanidine, nitro, alkyl, alkoxy or acyl;

X is a divalent hydrocarbon chain optionally substituted with hydroxyl, mercapto, halogen, amino, aminoalkyl, nitro, oxo or thio and optionally interrupted with N, O, S, SO or SO_2;

Y is a carbocycle or heterocycle optionally substituted with hydroxyl, mercapto, halogen, oxo, thio, thioalkyl, amino, aminoalkyl, carbocycle or heterocycle ring, hydrocarbon, a halo-substituted hydrocarbon, amino, amidine, guanidine, cyano, nitro, alkoxy or acyl;

L is a bond or a divalent hydrocarbon chain optionally substituted hydroxyl, halogen, oxo or thio and optionally interrupted with N, O, S, SO or SO_2 or an amino acid residue; less than 3 or 5 atoms

R_1 is H, OH, amino, O-carbocycle or alkoxy optionally substituted with amino, a carbocycle or heterocycle;

R_{2-5} are independently H, hydroxyl, mercapto, halogen, cyano, amino, amidine, guanidine, nitro or alkoxy; or R_3 and R_4 together form a fused carbocycle or heterocycle optionally substituted with hydroxyl, halogen, oxo, thio, amino, amidine, guanidine or alkoxy;

R_6 is H or a hydrocarbon chain optionally substituted with a carbocycle or a heterocycle; and

salts, solvates and hydrates thereof;

with the proviso that when Y is phenyl, R_2, R_4 and R_5 are H, R_3 is Cl and R_1 is OH then X is other than cyclohexyl.

2. A compound according to claim 1, wherein Cy is a 5- or 6-member non-aromatic heterocycle optionally substituted with hydroxyl, mercapto, thioalkyl halogen, oxo, thio, amino, aminoalkyl, amidine, guanidine, nitro, alkyl, alkoxy or acyl.

3. A compound according to claim 2, wherein said heterocycle comprises one or two heteroatoms and is optionally substituted with hydroxyl, oxo, mercapto, thio, alkyl or alkanoyl.

4. A compound according to claim 3, wherein said heterocycle is selected from the group consisting of piperidine, piperazine, morpholine, tetrahydrofuran, tetrahydrothiophene, oxazolidine, cyclopropa-pyrrolidine and thiazolidine optionally substituted with hydroxy, oxo, mercapto, thio, alkyl or alkanoyl.

5. A compound according to claim 4, wherein said heterocycle is selected from the group consisting of

piperidine, piperazine, morpholine, tetrahydrofuran, tetrahydrothiophene, oxazolidine, thiazolidine optionally substituted with hydroxy, oxo, mercapto, thio, alkyl or alkanoyl.

6. A compound according to claim 1, wherein Cy is a 3-6 member carbocycle optionally substituted with hydroxyl, mercapto, halogen, oxo, thio, amino, amidine, guanidine, alkyl, alkoxy or acyl.

7. A compound according to claim 6, wherein said carbocycle is partially unsaturated.

8. A compound according to claim 7, wherein Cy is cyclopropyl, cyclypropenyl, cyclobutyl, cyclbutenyl, cyclopentyl, cyclopentenyl cyclohexyl or cyclohexenyl.

9. A compound according to claim 1, wherein X is a C_{1-5} divalent hydrocarbon optionally having one or more carbon atoms replaced with N, O, S, SO or SO_2 and optionally being substituted with hydroxyl, oxo or thio.

10. A compound according to claim 1, wherein X is $-CH_2-NR_6-C(O)-$ wherein the carbonyl $-C(O)-$ portion thereof is covalently bound to Cy and R_6 is H or alkyl.

11. A compound according to claim 1, wherein Y is a carbocycle or heterocycle optionally substituted with hydroxyl or halogen.

12. A compound according to claim 11, wherein Y is furan-2-yl, thiophene-2-yl or phenyl, wherein said

phenyl is optionally substituted with halogen or hydroxyl.

13. A compound according to claim 1, wherein L is a divalent hydrocarbon optionally having one or more carbon atoms replaced with N, O, S, SO or SO_2 and optionally being substituted with hydroxyl, halogen oxo or thio; or three carbon atoms of the hydrocarbon are replaced with an amino acid residue.

14. A compound according to claim 13, wherein L is $-CH=CH-C(O)-NR_6-CH_2-$, $-CH_2-NR_6-C(O)-$, $-C(O)-N_6-CH_2-$, $-CH(OH)-(CH_2)_2-$, $-(CH_2)_2-CH(OH)-$, $-(CH_2)_3-$, $-C(O)-NR_6-CH(R_7)-C(O)-NR_6-$, $-NR_6-C(O)-CH(R_7)-NR_6-C(O)-$, $-CH(OH)-CH_2-O-$ or $-CH(OH)-CF_2-CH_2-$ wherein each R_6 is independently H or alkyl and R_7 is an amino acid side chain.

15. A compound according to claim 14, wherein R_1 is H, OH, amino, O-carbocycle or alkoxy optionally substituted with a carbocycle.

16. A compound according to claim 15, wherein R_1 is H or C_{1-4} alkyloxy.

17. A compound according to claim 1, wherein at least one of R_2 and R_3 is halogen and the other is H or halogen.

18. A compound according to claim 17, wherein R_2 and R_3 are both Cl.

19. A compound according to claim 18, wherein R_4 and R_5 are both H.

20. A pharmaceutical composition comprising a compound according to claim 1 with a pharmaceutically acceptable adjuvant, diluent or carrier.

21. A method of inhibiting binding of a LFA-1 to a protein ligand comprising contacting LFA-1 with a compound of claim 1.

22. A method of treating a disease or condition mediated by LFA-1 in a mammal comprising administering to said mammal an effective amount of a compound according to claim 1.

23. A method according to claim 23, wherein said disease or condition is arthritis, psoriasis, organ transplant rejection, asthma, and inflammatory bowel disease

23. A method of inhibiting an inflammatory disease or condition in a mammal comprising administering to said mammal an effective amount of a compound according to claim 1.